Home › All Companies › CRBP › Quarterly Report

Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Quarterly Report

AI-Powered SEC Filing Analysis

← All CRBP filings
Latest Quarterly Report Filed: 2026-05-12

Key Insights

  • The filing shows multiple subsequent events including an April 2026 lease agreement and a CSPC license agreement update as of April 30, 2026, indicating ongoing operational activities and potential strategic developments post-quarter end.
  • An open market sale agreement dated May 12, 2026 (filing date) suggests the company has established an at-the-market (ATM) offering program, providing flexible capital raising capability for liquidity management.
  • The document references multiple equity compensation plans (2014 and 2024 plans) with active restricted stock units and employee stock options across Q1 2026, indicating ongoing dilution from equity-based compensation programs.
  • Fair value measurements across multiple asset classes (commercial paper, corporate debt securities, money market funds) at varying hierarchy levels suggest diversified investment holdings, though the truncated content limits full assessment of liquidity position.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Corbus Pharmaceuticals Holdings, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.